Role of the molecular adsorbent recycling system (MARS) in the treatment of patients with acute exacerbation of chronic liver failure

@article{Sorkine2001RoleOT,
  title={Role of the molecular adsorbent recycling system (MARS) in the treatment of patients with acute exacerbation of chronic liver failure},
  author={Patrick Sorkine and Ron Ben Abraham and Oded Szold and Philippe Biderman and Ariel Kidron and Hadar Merchav and Shlomo Brill and Ran Oren},
  journal={Critical Care Medicine},
  year={2001},
  volume={29},
  pages={1332-1336}
}
ObjectiveTo test the efficacy of the molecular adsorbent recycling system (MARS) in patients with acute exacerbation of chronic liver disease. DesignA prospective case analysis. SettingA university-affiliated tertiary medical center. Patients and Methods We applied MARS to treat a consecutive series of eight patients with acute exacerbation of chronic liver disease. ResultsThe overall survival rate was 62.5%. All patients demonstrated improvement with regard to their degree of encephalopathy… 
First clinical experience with Molecular Adsorbent Recirculating System (MARS) in six patients with severe acute on chronic liver failure.
TLDR
A case series shows that MARS treatment in general can be safely performed in patients with severe liver disease, however, in Patients with an activated clotting system severe bleeding complication can be triggered and MARs treatment should be used very cautiously in these situations.
Application of Molecular Adsorbent Recirculating System in patients with severe liver failure after hepatic resection or transplantation: initial single-centre experiences.
TLDR
It is concluded that in surgical patients, acute liver failure is usually part of a complicated clinical course affecting multipleorgan systems and it is difficult to determine the specific influence of MARS on patient's outcome.
THIS ARTICLE HAS BEEN RETRACTED: An Australian Experience With the Molecular Adsorbents Recirculating System (MARS)
  • J. Kurtovic, M. Boyle, D. Bihari, S. Riordan
  • Medicine
    Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
  • 2006
TLDR
The findings suggest that MARS treatment might be associated with some clinical efficacy even in patients with advanced multi‐organ dysfunction occurring in the setting of severe liver damage and in whom treatment is instituted late in the clinical course, however the overall survival rate was poor.
The Molecular Adsorbent Recirculating System in patients with severe liver failure: clinical results at the K.U. Leuven.
TLDR
The molecular adsorbent recycling system (MARS) might be lifesaving in patients with severe liver failure of different aetiologies.
Review article: the Molecular Adsorbents Recirculating System (MARS) in liver failure
TLDR
Although the clinical experience with MARS is scarce, some pilot studies have reported its effectiveness at improving liver function and hepatic encephalopathy in patients with acute decompensation of chronic liver disease, and renal function in patientswith hepatorenal syndrome type I.
Equipment review: The molecular adsorbents recirculating system (MARS®)
TLDR
Preliminary experience with MARS therapy, instituted late in the clinical course of five patients with severely impaired liver function, indicates some clinical efficacy, but the overall survival rate remained poor and the overall impact on outcome remained poor.
Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment
TLDR
In patients with Cirrhosis, refractory ascites and type 1 HRS not responding to vasoconstrictor treatment, MARS is ineffective in improving systemic haemodynamics and renal function despite reduction in NO levels, suggesting that vasodilatation in advanced cirrhosis is not due to excess systemic vasodillators alone.
Review Equipment review: The molecular adsorbents recirculating
TLDR
Preliminary experience with MARS therapy, instituted late in the clinical course of five patients with severely impaired liver function, indicates some clinical efficacy, but the overall survival rate remained poor and the overall impact on outcome remained poor.
Cytokine level modifications: molecular adsorbent recirculating system versus standard medical therapy.
TLDR
The MARS liver support device corrected pathophysiologies of ALF and may be used to enhance spontaneous recovery or as a bridge to transplantation.
The role of the Molecular Adsorbents Recirculating System (MARS) in the management of liver failure
TLDR
The Molecular Adsorbents Recirculating System (MARS) is an extracorporeal liver support device based on dialysis across an albumin-impregnated membrane, using 20% albumin as dialysate and charcoal and anion exchange resin columns in the circuit help cleanse and regenerate the dialysates.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 28 REFERENCES
Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support.
TLDR
A new membrane separation system that is nearly impermeable to proteins but enables the exchange of water soluble and protein bound toxins by a special membrane and a recycled protein containing dialysate is described.
A Bioartificial Liver to Treat Severe Acute Liver Failure
TLDR
The bioartificial liver developed by the authors is safe and serves as an effective “bridge” to liver transplant in some patients and in vivo in experimental animals with liver failure.
Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial.
TLDR
A bioartificial liver to treat patients with severe liver failure until they can be either transplanted or recover spontaneously and the authors' clinical experience with the BAL has yielded encouraging results.
Determinants of ammonia clearance by hemodialysis.
TLDR
The results show that the clearance of ammonia is blood flow dependent and is also influenced by dialysate flow rate and dialyzer surface, and at clinically feasible conditions, ammonia can be extracted by more than 80% by setting the dialysatesate flow at a high rate.
A Carrier-Mediated Transport of Toxins in a Hybrid Membrane. Safety Barrier between a Patients Blood and a Bioartificial Liver
TLDR
The presented hybrid membrane may be used like an “intellegent membrane” as a safety barrier between the patients blood and cell devices and a significant reduction of protein bound toxins and a transport of metabolically relevant solutes, like amino acids, was shown.
A new procedure for the removal of protein bound drugs and toxins.
TLDR
The system effectively removed strongly albumin bound toxins like unconjugated bilirubin or free fatty acids from plasma and blood in vitro and in vivo and therefore could be considered a possible therapeutic means for the treatment of acute liver failure or acute and chronic intoxications with album in bound toxins, e.g., in drug overdose or chronic renal failure.
Cerebral oedema and increased intracranial pressure in chronic liver disease
TLDR
Cerebral oedema and increased intracranial pressure can occur in chronic liver disease and presents as neurological deterioration, but in most patients cerebral Oedema contributes to death or places them at too high a risk for liver transplantation.
Acute liver failure: redefining the syndromes
TLDR
Hyperacute liver failure is the authors' suggested term for cases in which encephalopathy occurs within 7 days of the onset of jaundice; this group includes the sizeable cohort likely to survive with medical management despite the high incidence of cerebral oedema.
Fulminant hepatic failure: Summary of a workshop
TLDR
There are no specific therapies for FHF, however, liver transplantation is recommended for situations in which spontaneous recovery appears unlikely and a suitable liver graft is available for transplantation.
Circulatory, respiratory, cerebral, and renal derangements in acute liver failure: pathophysiology and management.
TLDR
The use of N-acetylcysteine and prostacyclin, a vasodilator, have been shown to increase oxygen utilization in the microcirculation, suggesting that despite overproduction of NO in ALF, there is a short-age/ failure of utilization at a cellular level.
...
1
2
3
...